How do particle physicists learn the programming concepts they need?

The ability to read, use and develop code efficiently and successfully is a key ingredient in modern particle physics. We report the experience of a training program, identified as "Advanced Programming Concepts", that introduces software concepts, methods and techniques to work effectively on a daily basis in a HEP experiment or other programming intensive fields. This paper illustrates the principles, motivations and methods that shape the "Advanced Computing Concepts" training program, the knowledge base that it conveys, an analysis of the feedback received so far, and the integration of these concepts in the software development process of the experiments as well as its applicability to a wider audience.Comment: 8 pages, 2 figures, CHEP2015 proceeding

Establishment and characterization of a human papillary thyroid carcinoma cell line with oxyphilic differentiation (ONCO-DG 1)

In the present study the establishment and characterization of a new oxyphilic papillary thyroid carcinoma cell line--ONCO-DG1- is given. With immunohistological, histochemical and flow cytometric methods, ONCO-DG 1 cells revealed features of epithelial differentiation. Furthermore the cells formed von Kossa-positive deposits resembling psammoma bodies in monolayer and spheroid culture until late passages. The tumor cell line is now in the 40th subculture. Because of the ability to form multicellular tumor spheroids (MCTS), this cell line is a good model for examining the interaction between thyroid tumor cells and confluent human endothelial cells on extracellular matrix in vitro. It is also suitable for xenotransplantation studies, because it is tumorigenic in NMRI nude mice in vivo

Vi vill och vi kan – därför gör vi : Hur en arbetsgrupp och deras chef har hanterat och hanterar förändringsmotstånd

Abstract Thesis: We do because we want and we are able to -about a group and their manager and how they together have worked with, and today working with, resist to change. Programme: SO2030E:3, Linnaeus University Level: Bachelor Thesis Year/semester: Spring 2015 Authors: Pia Steinbach Mastenstrand and Rebecca Welander Supervisor: Magnus Persson Keywords: Change management, leadership, mechanism of inertia, power, quality improvement Background: The work with quality improvement within the geriatric care is a constant work in progress where implementation of new guidelines and routines is an essential part. This study highlights a workgroup that has over the last four years progressed from mainly not following new guidelines and routines to be successful in 2014 at the audit performed by The Health and Social Care Inspectorate where no deviations concerning quality were found. The purpose with this paper is to understand how the studied working group and their manager together have managed the resistance to change and the mechanics of inertia. Theory: Ahrne and Papakostas (2002) theory about the mechanism of inertia has been used to highlight the obstacles that are present in an organization during change management. Ahrne and Hedströms (1999) theory of distribution of power has been used to understand the managers power of position and how this can be used to manage change in a working group. Durkheim’s (2004) theory of structures describes the influence on the wellbeing of the employee. Method: A qualitative case study has been performed on a working group and their manager at a geriatric care home by interviews and observations, totally seven interviews and two meeting observations. Result: For a group that is functioning in a god way a lot of what the previous science provides about for example participation is important to work with to achieve quality improvement. But when a group is working in a dysfunction way and the context more or less is chaos, the manager first have to work with the structure. This to be able to make the group grow first before the members can participate in daily work and quality improvement. Thanks: Many thanks to the studied group and their manager for your time and thoughts about their work. Many thanks also to Magnus Persson that has guided us within the sociological way of thinking. Thanks for your time and your wise input

Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors.

Leptomeningeal dissemination of a primary brain tumor is a condition which is challenging to treat, as it often occurs in rather late disease stages in highly pretreated patients. Its prognosis is dismal and there is still no accepted standard of care. We report here a good clinical effect with a partial response in three out of nine patients and a stable disease with improvement on symptoms in two more patients following systemic anti-angiogenic treatment with bevacizumab (BEV) alone or in combination with chemo- and/or radiotherapy in a series of patients with leptomeningeal dissemination from primary brain tumors (diffuse astrocytoma WHO°II, anaplastic astrocytoma WHO°III, anaplastic oligodendroglioma WHO°III, primitive neuroectodermal tumor and glioblastoma, both WHO°IV). This translated into effective symptom control in five out of nine patients, but only moderate progression-free and overall survival times were reached. Partial responses as assessed by RANO criteria were observed in three patients (each one with anaplastic oligodendroglioma, primitive neuroectodermal tumor and glioblastoma). In these patients progression-free survival (PFS) intervals of 17, 10 and 20 weeks were achieved. In three patients (each one with diffuse astrocytoma, anaplastic astrocytoma and primitive neuroectodermal tumor) stable disease was observed with PFS of 13, 30 and 8 weeks. Another three patients (all with glioblastoma) were primary non-responders and deteriorated rapidly with PFS of 3 to 4 weeks. No severe adverse events were seen. These experiences suggest that the combination of BEV with more conventional therapy schemes with chemo- and/or radiotherapy may be a palliative treatment option for patients with leptomeningeal dissemination of brain tumors

Human tear fluid proteome dataset for usage as a spectral library and for protein modeling

This article provides a detailed dataset of human tear fluid proteins. Samples were fractionated by sodium dodecyl sulfate (SDS) gel electrophoresis resulting in 48 fractions that were spiked with an indexed retention time (iRT) peptide standard. These data are based on a data-dependent acquisition (DDA) mass spectrometric approach and can be used for example as a spectral library for tear fluid proteome analysis by data-independent acquisition (DIA). Moreover, the provided data set can be used with optimized HPLC and mass spectrometric settings for proteins/peptides of interest. Besides these aspects, this dataset can serve as a protein overview for gene ontology enrichment analysis and for modeling and benchmarking of multiple signaling pathways associated with the ocular surface in healthy or disease stages. The mass spectrometry proteomics data from the described workflow have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD011075

MRI scans before (a-e) and under (f-j) therapy.

<p><b>a, f:</b> Reduced leptomeningeal enhancement (white arrows) after 8 weeks of therapy with bevacizumab and lomustine in patient 3. <b>b, g:</b> Regression of leptomeningeal contrast-enhancing nodule (white arrow) on the septum pellucidum on T1-weighted images after eight weeks of therapy with bevacizumab and temozolomide in patient 4. <b>c, h:</b> This regression (black arrow) in patient 3 was also visible on T2-weighted images, which makes pure pseudoresponse unlikely. <b>d, i:</b> Regression of leptomeningeal contrast-enhancing nodules (white arrowheads) on the surface of the medullar conus and the lumbar nerve roots on T1 weighted images (Th10-L2) in patient 9 before and after radiotherapy plus eight weeks of therapy with bevacizumab and lomustine. <b>e, j:</b> This regression of contrast-enhancement (white arrowheads) in patient 9 was also apparent in the thoracic spine (Th5-Th9) which was not treated with radiotherapy.</p

Patient characteristics.

<p>Patient characteristics.</p

Intracellular Concentrations of Posaconazole in Different Compartments of Peripheral Blood▿

Therapeutic drug monitoring (TDM) of antifungal plasma concentrations is increasingly recommended. However, data on antifungal concentrations in the other compartments of the peripheral blood are limited. Hence, we collected 23 blood samples from 14 patients receiving posaconazole for prophylaxis of fungal infections. These samples were separated by double-discontinuous Ficoll-Hypaque density gradient centrifugation. The intracellular posaconazole concentrations of the obtained cells, i.e., the peripheral blood mononuclear cells (PBMCs), polymorphonuclear leukocytes (PMNs), and red blood cells (RBCs), were determined by liquid chromatography-tandem mass spectrometry. The intracellular concentrations of the PBMCs and PMNs were significantly higher than those of surrounding media (P < 0.001). The ratios between the intracellular and extracellular concentrations (C/E) were 22.5 ± 21.2, 7.66 ± 6.50, and 0.09 ± 0.05 for the PBMCs, PMNs, and RBCs, respectively. Posaconazole reaches high concentrations within human PBMCs and PMNs and is, to a lesser extent, present in RBCs. The high intracellular concentrations might contribute to posaconazole efficacy and distribution

Treatment and outcome.

<p>Treatment and outcome.</p